Pharmaceuticals that cause mammary gland tumors in animals: Findings in women

Breast Cancer Research and Treatment

Volumn 116, Issue 1, 2009, Pages 187-194

  Friedman, Gary D ^a,b   Jiang, Sheng Fang ^a   Udaltsova, Natalia ^a   Chan, James ^c   Quesenberry Jr , Charles P ^a   Habel, Laurel A ^a  

^a DIVISION OF RESEARCH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Breast neoplasms; Cyclophosphamide; Furosemide; Griseofulvin; Indomethacin; Isoniazid; Metronidazole; Nitrofurantoin; Pharmacoepidemiology; Reserpine

Indexed keywords

CYCLOPHOSPHAMIDE; FUROSEMIDE; GRISEOFULVIN; INDOMETACIN; ISONIAZID; METRONIDAZOLE; NITROFURANTOIN; RESERPINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DRUG INDUCED CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; ANTIBIOTICS, ANTIFUNGAL; ANTIPROTOZOAL AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIURETICS; FEMALE; FUROSEMIDE; GRISEOFULVIN; HUMANS; METRONIDAZOLE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHARMACOEPIDEMIOLOGY; RISK FACTORS; SEER PROGRAM; SENSITIVITY AND SPECIFICITY;

EID: 67649560376     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0123-1     Document Type: Article

References (25)

1. Rudel RA, Attfield KR, Schifano JN, Brody JG (2007) Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer (Supplement) 109:2635-2666 (Pubitemid 46906452)
2. SK Van Den Eeden GD Friedman 1995 Prescription drug screening for subsequent carcinogenicity Pharmacoepidemiol Drug Saf 4 275 287 10.1002/pds.2630040504
3. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA (2008) Screening statins for possible carcinogenic risk: up to nine years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 17:27-36. (Pubitemid 351166615)
4. N Krieger 1992 Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology Am J Public Health 82 703 710
5. Selby JV, Smith DH, Johnson E, Raebel MA, Friedman GD, McFarland BH (2005) The Kaiser Permanente Medical Care Program. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Inc, New York, pp 241-259
6. GD Friedman HK Ury 1980 Initial screening for carcinogenicity of commonly used drugs J Natl Cancer Inst 65 723 733 (Pubitemid 10059961)
7. GD Friedman HK Ury 1983 Screening for possible drug carcinogenicity: second report of findings J Natl Cancer Inst 71 1165 1175 (Pubitemid 14182047)
8. JV Selby GD Friedman BH Fireman 1989 Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up Cancer Res 49 5736 5747 (Pubitemid 19256461)
9. GD Friedman N Oestreicher J Chan CP Quesenberry Jr N Udaltsova LA Habel 2006 Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women Cancer Epidemiol Biomarkers Prev 15 2102 2106 10.1158/1055-9965. EPI-06-0401
10. Friedman GD, Selby JV (1989) Metronidazole and cancer. JAMA 261:866. Letter doi: 10.1001/jama.261.6.866b (Pubitemid 19046413)
11. GD Friedman 1983 Rauwolfia and breast cancer: no relation found in long-term users age fifty and over J Chronic Dis 36 367 370 10.1016/0021- 9681(83)90168-6 (Pubitemid 13130872)
12. Habel LA, Friedman GD (2006) Pharmaceuticals other than hormones. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 489-506
13. Lacey JV, Colditz GA, Schottenfeld D (2006) Exogenous hormones. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 468-488
14. Oehrli MD, Quesenberry CP, Leyden W (2006, November) Northern California cancer registry: 2006 annual report on trends, incidence, and outcomes. Kaiser Permanente, Northern California Cancer Registry
15. L Rodrigues BR Kirkwood 1990 Case-control designs in the study of common diseases: updates on the demise of the rare disease assumption and the choice of sampling scheme for controls Int J Epidemiol 19 205 213 10.1093/ije/19.1.205 (Pubitemid 20126858)
16. SAS Institute Inc (2004) SAS OnlineDoc® 9.1.2. SAS Institute Inc, Cary, NC
17. S Schneeweiss 2006 Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics Pharmacoepidemiol Drug Saf 15 291 303 10.1002/pds.1200
18. Friedman GD (2004) Primer of Epidemiology, 5th edn. McGraw-Hill, Inc, New York, pp 212-213
19. HM Tamin JA Hanley AH Hajeer J-F Boivin J-P Collet 2008 Risk of breast cancer in relation to antibiotic use Pharmacoepidemiol Drug Saf 17 144 150 (Pubitemid 351308513)
20. CM Velicer SR Heckbert JW Lampe JD Potter CA Robertson SH Taplin 2004 Antibiotic use in relation to risk of breast cancer JAMA 291 827 835 10.1001/jama.291.7.827
21. RC Didham DM Reith DW McConnell KS Harrison 2005 Antibiotic exposure and breast cancer in New Zealand Breast Cancer Res Treat 92 163 167 10.1007/s10549-005-2115-8
22. MM El-Mofti MH Shwaireb AE Essawy AM Risk HM Abdel-Kerim 1994 Induction of breast neoplasia and lung granulomas in mice by an antifungal drug (griseofulvin) Oncol Rep 1 1079 1081 (Pubitemid 2159523)
23. International Agency for Research on Cancer Some naturally occurring substances (1976) IARC monographs on the carcinogenic risk of chemicals to man, vol 10. International Agency for Research on Cancer, Lyon, France, pp 153-161
24. International Agency for Research on Cancer (1987) Overall evaluations of carcinogenicity: an updating of IARC monographs vols 1-42. IARC monographs on the carcinogenic risk of chemicals to man, supplement 7. International Agency for Research on Cancer, Lyon, France, p 391
25. International Agency for Research on Cancer Pharmaceutical Drugs (1990) IARC monographs on the carcinogenic risk of chemicals to man, vol 50. International Agency for Research on Cancer, Lyon, France, pp 277-291